SOLACI articles

2nd-generation drug-eluting stents, results for “real” patients at two years

Original title: Clinical Outcome Following Stringent Discontinuation of Dual Anti-Platelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: Two-Year Follow-up of the Randomized TWENTE Trial. Reference: Keneth T, Hanim S, et al. J Am Coll Cardiol 2013. Article in press.   In recent years there have been new drug-eluting

Current hemodialysis patients show similar results for sirolimus-eluting and paclitaxel

Original title: Drug-eluting stents in patients on chronic haemodialysis: Paclitaxel-eluting stents vs. limus –eluting stents Reference: Gabriel l. Sardi, et al. Cardiovasc Revasc Med. 2014 Mar;15(2):86-91. End Stage Renal Disease (ESRD) including renal failure on hemodialysis is associated with coronary heart disease and diabetes with subsequent need for revascularization that in this special population has a high

Validation of the Bleeding Academic Research Consortium

Reference: Circulation. 2012; 125:1424–143 Abstract: For many years all efforts applied to the optimization of percutaneous coronary intervention (PCI) were aimed specifically at reducing ischemic events risk through the advent of: 1) new devices (medicated stents), reducing restenosis rates, revascularization and 2) development of new drugs with a potent anti-platelet or anticoagulant such as clopidogrel or,

Angioplasty with stenting in ischemic stroke when thrombolytic agents won

Original title: A Controlled Trial of Revascularization in Acute Stroke. Reference: Martin Roubec et al. Radiology. 2012;Epub ahead of print. One of the most crucial forecast factors in patients undergoing acute ischemic stroke, stroke caused by a blockage in a brain artery, is the time window to recanalization.  Thrombolytic agents have been proved useful but not always achieve

Los resultados del sistema Corevalve® de Medtronic son superiores a la cirugía a corazón abierto a un año en un estudio fundamental de EE.UU

-Estudio de Alto Riesgo de CoreValve: La FDA Determina que No se Requiere un Panel de Expertos-Baja Tasa de Mortalidad Supera las Expectativas para el Punto Final Primario-El Sistema CoreValve es la Primera y Única Válvula Aórtica Transcatéter que Presenta Resultados Superiores al Reemplazo Quirúrgico de la Válvula Aórtica MINNEAPOLIS y WASHINGTON – 29 de

A moderate dose of midazolam and fentanyl is effective in reducing radial spasms 

Original title: Moderate Procedural Sedation and Opioid Analgesia During Transradial Coronary Interventions to Prevent Spasm. A Prospective Randomized Study. Reference: Spyridon Deftereos et al. J Am Coll Cardiol Intv 2013;6:267–73. The trans-radial approach has become the preferred diagnostic and therapeutic study for evidence of minor vascular complications, shorter hospital stays, less blood loss and better outcomes in acute